...
首页> 外文期刊>Indian drugs >DEVELOPMENT OF SUSTAINED RELEASE GASTRO-RETENTIVE TABLET FORMULATION OF BEPOTASTINE BESILATE USING QUALITY BY DESIGN (QBD) APPROACH
【24h】

DEVELOPMENT OF SUSTAINED RELEASE GASTRO-RETENTIVE TABLET FORMULATION OF BEPOTASTINE BESILATE USING QUALITY BY DESIGN (QBD) APPROACH

机译:通过设计(QBD)方法使用质量的培养嗜睡的嗜毒剂的开发嗜碱性的嗜毒剂

获取原文
获取原文并翻译 | 示例
           

摘要

The objective of the present study was to develop sustained release gastro-retentive (SRGR) tablet formulation of bepotastine besilate for once-a-day dosing using quality by design (QbD) approach. Quality target product profile (QTPP) of bepotastine besilate SRGR tablet formulation was defined and critical quality attributes (CQAs) were identifled. Potential risk factors were identified using fish bone diagram and failure mode effect analysis (FMEA) tool and screened by Plackett-Burman design and finally bepotastine besilate SRGR tablet formulation was optimized using Box-Behnken design. It was observed that formulation variables X_1 hydrophobic release controlling agent (mg/tab) and X_2: hydrophilic release controlling agent (mg/tab) have strikingly influenced drug release (%) (Y_1), while floating lag time (min) (Y_2) was significantly impacted by formulation variable X_4: gas generating agent (mg/tab). A design space plot within which the CQAs remained unchanged was established at lab scale. In conclusion, this study demonstrated the suitability of a hydrophobic-hydrophilic polymer combination along with gas generating agent to achieve SRGR tablet formulation for once-a-day dosing of bepotastine besilate using systematic QbD approach.
机译:None

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号